Oxandrolone
Oral Anabolic Steroid | Lean Mass & Recovery
Community Research
Join others researching Oxandrolone — share findings, ask questions, and learn from real experiences
Oxandrolone is a synthetic oral anabolic-androgenic steroid derived from dihydrotestosterone (DHT), first synthesized in 1962 by Raphael Pappo at Searle Laboratories and introduced to the market in 1964 under the brand name Anavar. It was designed to be a mild anabolic agent with minimal androgenic activity, achieved through a structural modification where an oxygen atom replaces the carbon-2 atom in the A-ring of the DHT backbone. This modification significantly reduces androgenic potency while preserving anabolic effects on skeletal muscle. Oxandrolone is FDA-approved for the promotion of weight regain following involuntary weight loss due to surgery, chronic infection, severe trauma, and prolonged corticosteroid use, and for the relief of bone pain associated with osteoporosis. It has been extensively studied in burn recovery, HIV/AIDS-related wasting, and pediatric growth disorders. Among oral anabolic steroids, oxandrolone is considered one of the mildest with respect to hepatotoxicity and virilizing side effects, which has made it one of the few anabolic steroids used in women and children in clinical settings.
Oxandrolone exerts its anabolic effects primarily through binding to the intracellular androgen receptor (AR), promoting nitrogen retention and protein synthesis in skeletal muscle tissue. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, which means it does not cause estrogen-mediated water retention or gynecomastia. The 2-oxo modification in the A-ring reduces its affinity for 5-alpha reductase, limiting conversion to more potent androgens in peripheral tissues and contributing to its relatively low androgenic profile. Oxandrolone increases protein synthesis through direct AR-mediated gene transcription, enhances the expression of genes involved in muscle hypertrophy and repair, and promotes collagen synthesis. It has also been shown to reduce cortisol-binding globulin levels and attenuate the catabolic effects of glucocorticoids, which is particularly relevant in burn patients and those recovering from severe trauma. Additionally, oxandrolone stimulates hepatic production of sex hormone-binding globulin (SHBG) to a lesser degree than other oral steroids, though it does suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis.
Molecular Data
Research Indications
FDA-approved for promoting weight regain following involuntary weight loss due to major surgery. Oxandrolone accelerates lean mass recovery and improves nitrogen balance during the recovery period.
Extensively studied in severe burn patients, where oxandrolone reduces protein catabolism, accelerates wound healing, shortens hospital stays, and improves long-term lean body mass outcomes. Widely used in major burn centers.
Effective for reversing muscle wasting and weight loss in patients with HIV/AIDS. Increases lean body mass and improves functional capacity in wasting syndrome.
FDA-approved indication for weight recovery after chronic infections that result in significant involuntary weight loss.
Counteracts catabolic effects of prolonged corticosteroid therapy by enhancing nitrogen retention and protein synthesis, helping preserve lean mass during necessary glucocorticoid treatment.
FDA-approved for relief of bone pain accompanying osteoporosis. Increases bone mineral density and reduces pain scores in osteoporotic patients, particularly postmenopausal women.
Used as adjunctive therapy with growth hormone in girls with Turner syndrome to improve final adult height. Clinical trials show additive benefit when combined with GH therapy.
Promotes nitrogen retention and anti-catabolic effects during energy restriction, preserving lean tissue while facilitating fat loss. Commonly used during cutting phases.
Increases muscular strength through enhanced protein synthesis and creatine phosphate regeneration, without the water retention associated with aromatizing compounds.
Clinical studies have demonstrated selective reduction in abdominal and visceral adipose tissue with oxandrolone treatment, independent of total caloric intake changes.
Dosing Protocols
Oxandrolone is exclusively administered orally as a 17-alpha-alkylated steroid. It is available in tablet form, typically in 2.5 mg, 5 mg, and 10 mg doses. The 17-alpha-methylation provides resistance to first-pass hepatic metabolism, allowing adequate oral bioavailability. Despite the alkylation, oxandrolone is among the least hepatotoxic of oral anabolic steroids, though liver function should still be monitored during use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Medical - Weight Recovery | 2.5-20 mg/day | Divided into 2-4 doses daily | Oral |
| Medical - Burn Recovery | 0.1 mg/kg twice daily | Twice daily | Oral |
| Performance - Male (Conservative) | 20-30 mg/day | Split into 2 doses (morning and evening) | Oral |
| Performance - Male (Standard) | 40-50 mg/day | Split into 2 doses (morning and evening) | Oral |
| Performance - Female | 5-20 mg/day | Split into 2 doses or taken once daily | Oral |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- HDL cholesterol suppression (dose-dependent, most significant lipid effect)
- LDL cholesterol elevation
- Mild hepatic stress (elevated liver enzymes ALT/AST)
- Suppression of endogenous testosterone production
- Mild headaches
- Nausea or gastrointestinal discomfort
- Changes in libido (increase or decrease depending on hormonal context)
- Oily skin and mild acne
Stop Signs - Discontinue if:
- Yellowing of skin or eyes (jaundice, indicating significant hepatic dysfunction)
- Severe or persistent abdominal pain, especially in the upper right quadrant
- Dark-colored urine or clay-colored stools (signs of liver injury)
- Unusual or prolonged bleeding or bruising
- Severe swelling of the extremities
- Signs of virilization in women that persist or worsen (discontinue immediately)
- Chest pain, difficulty breathing, or signs of cardiovascular distress
Contraindications
- Known or suspected prostate cancer
- Breast cancer in males
- Breast cancer with hypercalcemia in females
- Pregnancy (Category X - known to cause fetal harm)
- Nephrosis or nephrotic phase of nephritis
- Hypercalcemia
- Severe hepatic dysfunction or active liver disease
- Hypersensitivity to oxandrolone or any formulation component
Quality Checklist
Good Signs
- Pharmaceutical-grade product with valid NDC number and manufacturer lot (Oxandrin or authorized generic)
- Proper labeling with correct dosage per tablet (2.5 mg, 5 mg, or 10 mg), lot number, and expiration date
- Tablets are uniform in size, color, and shape with consistent imprinting
- Prescribed by a licensed physician with documented clinical indication
- Stored in original packaging, protected from moisture and light
- Third-party lab testing confirming identity, potency, and absence of contaminants
Warning Signs
- Underground lab (UGL) product without pharmaceutical-grade verification
- Tablets with inconsistent sizing, crumbling, or no imprint
- Product labeled at unusually high doses per tablet (above 50 mg)
- No third-party certificate of analysis available
- Packaging that appears unprofessional or has spelling errors
Bad Signs
- Product with no labeling or verifiable source information
- Lab testing reveals underdosed or substituted compound (common with UGL oxandrolone)
- Presence of methyl-1-testosterone or other substituted compounds instead of actual oxandrolone
- Contaminated product with heavy metals, bacteria, or undisclosed active ingredients
- Expired product or product stored improperly (excessive heat, moisture exposure)
- Severe or unexpected side effects suggesting mislabeled or adulterated product
References
- Oxandrolone in the Treatment of Burn Injuries: A Systematic Review and Meta-AnalysisLi, H., Guo, Y., Yang, Z., Roy, S.K., Tlszczuk, A.Burns (2017)
Systematic review confirming that oxandrolone significantly improves lean body mass, reduces weight loss, shortens hospital length of stay, and accelerates donor site healing in burn patients. Demonstrated a favorable safety profile with mild transient hepatic enzyme elevations as the primary adverse effect.
- Long-Term Oxandrolone Use in Children With Severe BurnsPorro, L.J., Herndon, D.N., Rodriguez, N.A., et al.Journal of Pediatric Surgery (2012)
Long-term administration of oxandrolone (up to 12 months) in severely burned children improved lean body mass, bone mineral content, and muscle strength without clinically significant hepatotoxicity or premature epiphyseal closure, supporting its safety for extended use in pediatric burn patients.
- Oxandrolone for the Treatment of Weight Loss Associated with HIV InfectionBerger, J.R., Pall, L., Hall, C.D., Simpson, D.M., Berry, P.S., Dudley, R.AIDS (1996)
Randomized controlled trial demonstrating that oxandrolone at 20 mg/day significantly increased body weight and lean body mass in HIV-infected men with weight loss, while being well-tolerated with minimal adverse effects over the 16-week study period.
- Effects of Oxandrolone on Outcome Measures in the Severely Burned: A Multicenter Prospective Randomized Double-Blind TrialWolf, S.E., Thomas, S.J., Dasu, M.R., et al.Journal of Burn Care & Research (2006)
Multicenter RCT of 81 severely burned adults showing oxandrolone (10 mg twice daily) significantly reduced net nitrogen loss, decreased time to wound closure by 25%, and improved body composition during the acute recovery phase compared to placebo.
- Oxandrolone in Trauma PatientsDemling, R.H., DeSanti, L.Annals of Surgery (2003)
Demonstrated that oxandrolone (20 mg/day) in major trauma patients restored lean body mass to pre-injury levels significantly faster than controls, while also improving wound healing rates and functional recovery measures during rehabilitation.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.